Since its inception in 2017, Connecticut-based InveniAI has revolutionized drug discovery by leveraging artificial intelligence (AI), machine learning, and generative AI to enhance efficiency and success rates. Led by President and CEO Dr. Krishnan Nandabalan, Ph.D., a biotech veteran, the company stands at the intersection of innovation and collaboration, particularly with its strong ties to Japan.
Nandabalan highlights InveniAI’s mission: “AI is our force multiplier, enabling us to comprehensively analyze massive datasets and accelerate the drug discovery process.” The company’s AI platform, AlphaMeld®, has been instrumental in overcoming the traditionally low success rates in pharmaceutical development by streamlining research, maximizing both safety and efficacy, and reducing time-to-market.
Japan, a leader in technological innovation, has been an early adopter of InveniAI’s technology. Collaborations with renowned Japanese pharmaceutical giants like Takeda, Kyowa Kirin, Shionogi, and Daiichi Sankyo underscore the trust and synergy between the two markets. Aman Kant, InveniAI’s Chief Business Officer, notes, “Japanese companies value technology’s transformative potential. They recognize AI as a bridge to compete globally and bring innovative solutions to the U.S. market.”
InveniAI’s notable achievement with Daiichi Sankyo involved identifying a shelved drug compound using its AI platform. The partnership rejuvenated this compound, targeting chronic inflammatory diseases such as chronic urticaria and atopic dermatitis. “This collaboration resulted in the creation of Invea Therapeutics, a spin-out from InveniAI dedicated to developing a drug portfolio targeting immune-mediated inflammatory disorders, exemplifying the global potential of AI-driven solutions,” says Kant. “It’s about creating patient-centered innovations that benefit not just the U.S. and Japan but the world.”
As healthcare demands evolve, InveniAI is expanding its AI capabilities from target identification to the design of small molecule and antibody drugs––areas poised to address unmet medical needs. By integrating U.S. technological advancements with Japan’s precision and ambition, InveniAI exemplifies a model for cross-border collaboration.
“We aim to redefine healthcare’s future,” shares Dr. Nandabalan. With its strong foundation and focus on innovation, InveniAI is set to deepen its impact, driving global healthcare solutions through its enduring partnership with Japan.
